Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 14/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932066 | 0.91 | RORC (0.48) | RORCPPARGMAPT | |
| SCHEMBL1930914 | 0.88 | MAPT (0.51) | RORCPPARGMAPTRAD51TP53 | |
| SCHEMBL1931167 | 0.84 | MAPT (0.51) | RORCMAPTTP53 | |
| SCHEMBL29389090 | 0.84 | RORC (0.56) | RORCPPARGMAPTTP53MAP2K3 | |
| SCHEMBL1931838 | 0.82 | MAPT (0.44) | RORCPPARGMAPTRAD51MAP2K3 | |
| SCHEMBL1572758 | 0.80 | FNTA (0.44) | RORC | |
| SCHEMBL1932592 | 0.79 | MAPT (0.45) | RORCPPARGMAPTRAD51MAP2K3 | |
| SCHEMBL321531 | 0.78 | FNTA (0.46) | RORCMAPT | |
| SCHEMBL322566 | 0.78 | RORC (0.43) | RORCPPARGMAPTMAP2K3 | |
| SCHEMBL1932541 | 0.78 | RORC (0.50) | RORCPPARGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633216-B2 | Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI (FR) | 2014-01-21 | — | — | US | disclosed |
| US-8008321-B2 | Imidazo[1,5-a]pyridin-3-yl)(3-methoxy-4-nitrophenyl)methanone; a and b fibroblast growth factor receptors (FGFR) antagonist; anticarcinogenic, antitumor: lung, breast, prostate, melanomas, gliomas; antiinflammatory, vascular smooth muscle cells: atherosclerosis, restenosis, stent and bypass complications | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | CYP3A5, CYP4B1, CYP3A7 | RORC 279/4885PPARG 1094/4885MAPT 2878/4885 |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | P2RX6, IL5, ATIC | RORC 464/4885PPARG 770/4885MAPT 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.